LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

News & Events

5 02, 2021

FDA provides new guidance to industry on manufacture of cell and gene therapy products during COVID-19 pandemic

2024-07-10T19:48:09+00:00

The Center for Biologics Evaluation and Research (CBER) regulates cellular therapy products, human gene therapy products, and certain devices related to cell and gene therapy. CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight. Cellular therapy products include cellular immunotherapies, cancer vaccines, [...]

FDA provides new guidance to industry on manufacture of cell and gene therapy products during COVID-19 pandemic2024-07-10T19:48:09+00:00
7 12, 2020

Avance Biosciences™ Recognized as Top 10 Genomics Solutions Company

2022-05-05T13:21:09+00:00

Pharm Tech Outlook, a highly respected pharmaceutical/biotech industry magazine, has recognized Avance Biosciences™ as a top 10 Genomics Solutions Company for 2020. Genomic technologies and their usage have seen extensive growth in the past decade. Over the years, these technologies have evolved significantly and can now be used [...]

Avance Biosciences™ Recognized as Top 10 Genomics Solutions Company2022-05-05T13:21:09+00:00
16 10, 2020

MASS General researchers show ddPCR brain tumor liquid biopsy assay has tenfold improvement in sensitivity over any prior assay

2024-07-13T13:35:57+00:00

Genetic mutations that promote the growth of the most common type of adult brain tumors can be accurately detected and monitored in blood samples using an enhanced form of liquid biopsy developed by researchers at Harvard-affiliated Massachusetts General Hospital (MGH). Comparing blood samples from patients with gliomas with tumor biopsy tissues from the same patients, [...]

MASS General researchers show ddPCR brain tumor liquid biopsy assay has tenfold improvement in sensitivity over any prior assay2024-07-13T13:35:57+00:00
12 08, 2020

FDA approves first liquid biopsy next-generation sequencing companion diagnostic test

2020-08-12T13:40:43+00:00

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to [...]

FDA approves first liquid biopsy next-generation sequencing companion diagnostic test2020-08-12T13:40:43+00:00
19 06, 2019

Phage Testing of Bacterial Cultures

2024-07-13T13:15:09+00:00

Regulatory agencies require companies using microbial cell lines that produce products for human use to regularly complete biosafety testing to ensure that cell banks are free of phage contamination. Bacteriophage (phage) is a virus that infects and replicates within bacteria1, basically bacterial predators. One hundred times smaller than a bacterium, phage are found wherever [...]

Phage Testing of Bacterial Cultures2024-07-13T13:15:09+00:00
11 06, 2019

NGS for Biologics Development Support

2022-04-29T14:49:53+00:00

NGS represents a technological leap that has potential to revolutionize drug discovery and development. Next Generation Sequencing (NGS) has the potential to unlock causative factors from our genetic material. NGS also represents a technological advancement using array-based sequencing that will improve many aspects of scientific research and advance the field of personalized medicine. Because [...]

NGS for Biologics Development Support2022-04-29T14:49:53+00:00
30 10, 2018

Avance Biosciences™ Completes Successful FDA Inspection

2023-04-11T14:25:35+00:00

HOUSTON, Oct. 30, 2018 - Avance Biosciences™, Inc., a leading biological testing company supporting drug development and manufacturing, announced today that its Houston facility was inspected by the U.S. Food and Drug Administration on October 01 through October 04, 2018.  This inspection focused on the firm’s quality management system, operation procedures, and data integrity, as [...]

Avance Biosciences™ Completes Successful FDA Inspection2023-04-11T14:25:35+00:00
16 05, 2018

Digital PCR Services

2022-04-29T15:06:31+00:00

Digital PCR (dPCR) provides precise and absolute quantification of nucleic acids without a standard curve and without dependence on amplification efficiency.Digital PCR is ultrasensitive; therefore, appropriate for testing allelic variants and targets of low abundance that are below the sensitivity limit of QPCR. It is also very precise, and is a better tool than QPCR when precise determination of the ratio of several nucleic acid sequences is required.

Digital PCR Services2022-04-29T15:06:31+00:00
25 03, 2012

Avance Biosciences™ Signed MSA

2024-11-12T13:49:51+00:00

In the week of March 18, 2012, Avance Biosciences™ entered a Master Service Agreement (MSA) with a global leader in custom biologics manufacturing. Based on this agreement, Avance Biosciences™ will provide its GMP level Cell Bank Characterization services, including DNA Sequencing, qPCR, Southern blot and other molecular biological methods, to characterize the Master Cell Bank (MCB), Working Cell Bank (WCB), and End of Production Cells (EOPC) submitted by the clients.

Avance Biosciences™ Signed MSA2024-11-12T13:49:51+00:00
5 07, 2011

New Website – Avance Biosciences™ Inc.

2024-11-12T13:50:03+00:00

  To Our Esteemed Customers and Friends: We would like to bring to your attention that Avance Biosciences™ Inc. has been formed by a group of experienced genomic scientists, quality professionals, biotechnology services experts, and enthusiastic investors.  The founders of the company, combined, have more than 100 years of experience in the genomics and biotechnology [...]

New Website – Avance Biosciences™ Inc.2024-11-12T13:50:03+00:00
Go to Top